<DOC>
	<DOCNO>NCT01173445</DOCNO>
	<brief_summary>The purpose study see researcher detect circulate tumor cell ( CTC ) circulate endothelial cell ( CEC ) blood .</brief_summary>
	<brief_title>Circulating Tumors Cells Circulating Endothelial Cells Renal Cell Carcinoma</brief_title>
	<detailed_description>Circulating tumor cell ( CTCs ) circulate endothelial cell ( CECs ) find peripheral blood common malignancy promise surrogate biomarkers . The CellSearchTM CTC assay currently approve Food Drug Administration adjunct monitor disease status breast , prostate colon carcinoma ; evidence breast cancer suggest CTCs independent predictor overall survival progression-free survival . Evolving data demonstrate potential role CTCs surrogate assessment treatment response . The benefit approach renal cell cancer ( RCC ) unknown investigation need determine feasibility use CellSearchTM CTC Assay malignancy . Circulating endothelial cell ( CECs ) increase peripheral blood cancer patient appear marker tumor related angiogenesis . Studies suggest CECs increase set progressive disease decrease response treatment antiangiogenic agent . Although current data evaluate CECs RCC limit , significant interest CEC evaluation marker treatment response give majority current FDA approve RCC therapy target tumor angiogenesis . The overall objective protocol obtain preliminary data experience use Cell Search Assay system use future grant application . Our hypothesis CTCs and/or CECs valuable versatile biomarkers therapeutic response , determination relapse survival patient renal cell cancer .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Any patient radiographic histologic evidence renal cell carcinoma schedule begin treatment one follow antiangiogenic agent : sunitinib , sorafenib , temsirolimus bevacizumab . Patients must candidate treat one agent limit number prior therapy ( i.e . first line subsequent treatment set ) . Patients schedule undergo debulking nephrectomy prior begin systemic therapy require histologic diagnosis prior baseline test . Must able willing sign inform consent . Patients must 18 year old .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>cancer</keyword>
	<keyword>kidney</keyword>
	<keyword>renal cell</keyword>
	<keyword>tumor cell</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>circulate endothelial cell</keyword>
</DOC>